Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Moodys
Queensland Health
Covington
Cipla
McKinsey

Generated: August 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,012,462

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,012,462 protect, and when does it expire?

Patent 9,012,462 protects ALUNBRIG and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.

Summary for Patent: 9,012,462
Title:Phosphorous derivatives as kinase inhibitors
Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. ##STR00001##
Inventor(s): Wang; Yihan (Newton, MA), Huang; Wei-Sheng (Acton, MA), Liu; Shuangying (Wellesley, MA), Shakespeare; William C. (Southborough, MA), Thomas; R. Mathew (Sharon, MA), Qi; Jiwei (West Roxbury, MA), Li; Feng (Winchester, MA), Zhu; Xiaotian (Newton, MA), Kohlman; Anna (Winchester, MA), Dalgarno; David C. (Brookline, MA), Romero; Jan Antoinette C. (Somerville, MA), Zou; Dong (Concord, MA)
Assignee: Ariad Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/736,910
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,012,462

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-001 Apr 28, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-002 Apr 28, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-003 Oct 2, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,012,462

PCT Information
PCT FiledMay 21, 2009PCT Application Number:PCT/US2009/044918
PCT Publication Date:November 26, 2009PCT Publication Number: WO2009/143389

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Teva
AstraZeneca
Farmers Insurance
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.